Patient-Reported Outcomes with Roflumilast Foam 0.3% in Patients with Psoriasis of the Scalp and Body in the Phase 3 ARRECTOR Trial. J of Skin [Internet]. 2025 Mar. 17 [cited 2026 Apr. 30];9(2):s525. Available from: https://skin.dermsquared.com/skin/article/view/3265